Table 1 mRNA vaccine clinical trials for cancer

Personalized mRNA vaccine (Autogene Cevumeran)

Atezolizumab

Advanced tumors including pancreatic cancer

I

NCT03289962

Genentech, (collaborator: BioNTech)

[60]

Atezolizumab, mFOLFIRINOX

Pancreatic cancer

II

NCT05968326

Personalized mRNA vaccine

N/A

Esophageal cancer, NSCLC

I

NCT03908671

Stemirna Therapeutics

Sintilimab

Advanced solid tumor

I

NCT05949775

Personalzed mRNA vaccine SW1115C3

N/A

Solid tumor

I

NCT05198752

Personalized mRNA vaccine

N/A

Esophageal, gastric, pancreatic, and colon cancers

I

NCT03468244

Changhai Hospital, Shanghai

Personalized mRNA vaccine

Sintilimab

Liver cancer

I

NCT05761717

Shanghai Zhongshan Hospital

Personalized neoantigen mRNA vaccine

N/A

Solid tumor

I

NCT05359354

Peking Union Medical College Hospital

EBV mRNA vaccine

N/A

EBV-positive advanced malignant tumors

I

NCT05714748

West China Hospital

HBV mRNA vaccine

N/A

HBV-positive liver cancer

I

NCT05738447

Peking Union Medical College Hospital

BNT113 (HPV16 E6/E7 mRNA- LPX vaccine)

Pembrolizumab

HPV16 + _head and neck cancer, PDL1 postive

II

NCT04534205

BioNTech SE

Neoantigen mRNA vaccine ABOR2014(IPM511)

NA

Liver cancer

I

NCT05981066

Peking Union Medical College Hospital

mRNA neoantigen tumor vaccine

Combination with PD-1/L1

Gastric cancer, esophageal cancer, liver cancer

I

NCT05192460

NeoCure

DCs loaded with mRNA from tumor tissue, hTERT and Survivin

N/A

Prostate cancer

I/II

NCT01197625

Oslo university hospital

CV9103 mRNA

Prostate cancer

I/II

NCT00831467

CureVac

[65]

BNT112 containing mRNA targeting 5 antigens expressed in prostate cancder (RNA-LPX)

Cemiplimab

Prostate cancer

I

NCT04382898

BioNTech SE

Tumor mRNA-lipid particles(LPs)

N/A

Lung cancer

I

NCT05660408

University of Florida

mRNA vaccine BI1361849 (CV9202)

Anti-PDL1 Durvalumab

Anti-CTLA3 Tremelimumab

NSCLC

Results posted on Clinicaltrials.gov

I/II

NCT03164772

Ludwig Institute for cancer research

V941(mRNA-5671/V941)

Pembrolizumab

NSCLC, colorectal cancer or pancreatic cancer

I/II

NCT03948763

Completed

Merck Sharp & Dohme LLC

mRNA-4157

Pembrolizumab

Solid tumor

I

NCT03313778

ModernaTX, Inc

WT1 mRNA loaded DCs

Combined with Chemotherapy

Malignant pleural mesothelioma

I/II

NCT02649829

University Hospital, Antwerp

TAA-loaded DCs

N/A

Colorectal cancer

I/II

NCT01885702

Radboud University

CEA mRNA and peptide loaded DCs (electroporated)

Colorectal cancer

I

NCT00228189

Radbound Universtity Medical Cener

[71]

Personalized primary tumor mRNA loaded DOTAP liposome vaccine

Anti-PD1

Melanoma

I

NCT05264974

University of Florida

mRNA-4157

Pembrolizumab

Melanoma

II

NCT03897881

Moderna TX, Inc

[74]

DCs-loaded with TAA mRNA

N/A

Melanoma

I

NCT01456104

Memorial Sloan Kettering Cancer Center

TriMix-DC (mRNA-loaded DCs)

Melanoma

I

NCT01066390

Universitair Ziekenhuis Brussel

[66, 67]

Tumor mRNA transfected DCs

IL-2

Melanoma

I/II

NCT01278940

Olso University Hospital

[70]

mRNA encoding Melan-A, MAGE-A1, MAGE-A3, Survivin, GP100 and Tyrosinase

GM-CSF s.c

Melanoma

I/II

NCT00204607

University Hospital Tuebingen

[63]

NCI-4650 mRNA vaccine (personalized)

Melanoma or epithelial cancer

I/II

NCT03480152

NCI

[16]

CT7, MAGE-A3 and WT1 mRNA-electroporated Langerhans cells (LCs)

Multiple myeloma

I

NCT01995708

Memorial Sloan Kettering Cancer Center

[73]

WT1 mRNA-DCs

N/A

AML

II

NCT01686334

Zwi Berneman

WT1 mRNA -DCs

N/A

Myelodysplastic syndromes, AML

I/II

NCT03083054

University of Campinas, Brazil

WT1 mRNA-DCs

AML

I/II

NCT00834002

University Hospital, Antwerp

[72]

GRNVAC1 mRNA encoding hTERT-LAMP1 -DCs

AML

II

NCT00510133

Asterias Biotherapeutics, Inc

mRNA plus lysate-loaded DCs

Pegylated-interferon alpha-2A and Filgrastim

Cutaneous Angiosarcoma

I

NCT05799612

MD Anderson Cancer Center

CMV-DC (CMV pp65-LAMP mRNA-loaded DC)

Tetanus toxoid

GBM

I/II

NCT00639639

Duke University

DCs transfected with mRNA from tumor stem cells, surviving and hTERT

Adjuvant temozolomide

GBM

II/III

NCT03548571

Oslo University Hospital

CMV pp65-LAMP mRNA-pulsed autologous DC vaccine

N/A

GBM

I

NCT02366728

Duke University

WT1 mRNA-loaded DC vaccine

Temozolomide

Glioma

I/II

NCT04911621

University Hospital, Antwerp

Personalized primary tumor mRNA and full length of pp65-LAMP (RNA-LPs)

N/A

pHGG and GBM

I

NCT04573140

University of Florida

CV09050101 mRNA

N/A

GBM or astrocytoma

I

NCT05938387

CureVac

CMV-pp65-LAMP mRNA- loaded DCs

Varillumab and Temozolomide

GBM

II

NCT03688178

Duke University

CMV pp65-LAMP mRNA-loaded DCs

CMV-ALT, GM-CSF

GBM

I/II

NCT00639639

Duke University

[76, 77]

CMV mRNA DCs

Nivolumab

GBM

I/II

NCT02529072

Duke University

pp65-shLAMP mRNA-DCs

Td, and GM-CSF

GBM

II

NCT02465268

Immunomic Therapeutics, Inc

WT1 mRNA-loaded DCs

Temozolomide

GBM

I/II

NCT02649582

Unviersity Hospital, Antwerp

Tumor stem cell derived mRNA-transfected DCs

Combined with standard treatment

GBM

I/II

NCT00846456

Oslo University Hospital

[75]

Personalized mRNA-DCs

GBM

I/II

NCT02709616

Guangdong 999 Brain Hospital

[78]